MicroMed raises $23 million:
This article was originally published in Clinica
MicroMed Technology has raised $23m in a private placement to new and existing investors. The proceeds will fund the European commercialisation of the Houston, Texas company's main product, the DeBakey ventricular assist device (VAD), which has received CE mark approval. It will also be spent on US clinical trials of the product as a bridge to heart transplant and for patients for whom a heart transplant is contra-indicated. The company says it will also close a $5m bank line of credit soon.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.